Federico Pea at University of Bologna - Research Interests, Publications & Academic Profile

Federico Pea

Full Professor of Pharmacology

University of Bologna

Italy

This profile is automatically generated from trusted academic sources.

Google Scholar

ORCID

How do Nigerian students reach out?

Meet Kite AI

Contact this professor

ORCID

Google Scholar

Research Interests

Pharmacotherapy

100%

Pharmacology

70%

Antibiotic Therapy

100%

Pharmacokinetic

50%

Antifungal Therapy

50%

Pharmacometrics

40%

Renal Replacement Therapy

40%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles20

An innovative population pharmacokinetic/pharmacodynamic strategy for attaining aggressive joint PK/PD target of continuous infusion ceftazidime/avibactam against KPC- and OXA-48- producing Enterobacterales and preventing resistance development in critically ill patients

Article Link

Year:

2024

Balancing the scales: achieving the optimal beta-lactam to beta-lactamase inhibitor ratio with continuous infusion piperacillin/tazobactam against extended spectrum beta-lactamase producing Enterobacterales

Article Link

Year:

2024

Piperacillin-tazobactam vs. carbapenems for treating hospitalized patients with ESBL-producing Enterobacterales bloodstream infections: A systematic review and meta-analysis

Article Link

Year:

2024

Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion meropenem/vaborbactam in a case series of orthotopic liver transplant recipients

Article Link

Year:

2024

Impact of Inflammatory Burden on Voriconazole Exposure in Oncohematological Pediatric Patients Receiving Antifungal Prophylaxis after Allogeneic HCT

Article Link

Year:

2024

In reply to the Letter to the Editor regarding “Clinical efficacy of cefiderocol-based regimens in patients with carbapenem-resistant Acinetobacter baumannii infections: A systematic review with meta-analysis”

Article Link

Year:

2024

Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post‐neurosurgical extensively/multidrug‐resistant Gram‐negative bacteria‐related meningitis/ventriculitis in the current era of novel beta‐lactams and beta‐lactam/beta‐lactamase inhibitor combinations?

Article Link

Year:

2024

A Sensitive Liquid Chromatography–Tandem Mass Spectrometry Method for Measuring Fosfomycin Concentrations in Human Prostatic Tissue

Article Link

Year:

2024

Efficacy of a Novel Prophylactic Scheme of Fosfomycin Trometamol in Patients Undergoing Endoscopic Surgery for Benign Prostatic Hyperplasia: Findings from a Prospective Monocentric Single-Arm Study

Article Link

Year:

2024

Novel CMY-186 variant conferring cross-resistance to cefiderocol and ceftazidime/avibactam in Klebsiella pneumoniae from a critically ill patient during cefiderocol and ceftazidime/avibactam treatment

Article Link

Year:

2024

Invasive Candida infection: epidemiology, clinical and therapeutic aspects of an evolving disease and the role of rezafungin

Article Link

Year:

2023

Safety of high loading doses of teicoplanin: POSY-TEICO, a prospective, multicentre, observational study

Article Link

Year:

2023

Pharmacokinetic/pharmacodynamic target attainment of continuous infusion ceftazidime-avibactam in peritoneal fluid in an orthotopic liver transplant recipient affected by bacteraemic complicated intra-abdominal infection due to OXA-181-producing Klebsiella pneumoniae

Article Link

Year:

2023

Pharmacokinetic/Pharmacodynamic Target Attainment of Continuous Infusion Piperacillin–Tazobactam or Meropenem and Microbiological Outcome among Urologic Patients with Documented Gram-Negative Infections

Article Link

Year:

2023

Comment on: pharmacokinetics/pharmacodynamics and therapeutic drug monitoring of ceftazidime/avibactam administered by continuous infusion in patients with MDR Gram-negative bacterial infections

Article Link

Year:

2023

A descriptive case series of the relationship between maintenance of conservative PK/PD efficacy thresholds of dalbavancin over time and clinical outcome in long-term treatment of staphylococcal osteoarticular infections

Article Link

Year:

2023

Impact of Inflammation on Voriconazole Exposure in Critically ill Patients Affected by Probable COVID-19-Associated Pulmonary Aspergillosis

Article Link

Year:

2023

Fast and Sensitive Method for Simultaneous Quantification of Meropenem and Vaborbactam in Human Plasma Microsamples by Liquid Chromatography–Tandem Mass Spectrometry for Therapeutic Drug Monitoring

Article Link

Year:

2023

A novel method to evaluate ceftazidime/avibactam therapy in patients with carbapenemase-producing Enterobactericeae (CPE) bloodstream infections

Article Link

Year:

2023

Does Cytokine-Release Syndrome Induced by CAR T-Cell Treatment Have an Impact on the Pharmacokinetics of Meropenem and Piperacillin/Tazobactam in Patients with Hematological Malignancies? Findings from an Observational Case-Control Study

Article Link

Year:

2023

Collaborators5

Mario VENDITTI

full professor of medicine and Infectious diseases

Università degli Studi di Roma La Sapienza

ITALY

Manjunath Pai

Professor and Chair

University of Michigan

UNITED STATES

Vincent H Tam

University of Houston College of Pharmacy

UNITED STATES

Alessandra Oliva

ITALY

Paolo Gaibani

ITALY

How do Nigerian students reach out?

Meet Kite AI